{
    "nctId": "NCT03036462",
    "officialTitle": "Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality - FAIR-HF2",
    "inclusionCriteria": "1. Patients with chronic HFrEF (CHF) of at least 3 months duration and a history of documented LVEF\\<45%.\n2. Confirmed presence of ID (ferritin \\< 100 ng/mL or ferritin 100 - 299 ng/mL with TSAT \\< 20 %)\n3. Serum haemoglobin of 9.5 - 14.0 g/dL\n4. At time of screening considered re-stabilised and planned for discharge within next 24 h (NYHA 2 or 3), or stable ambulatory with a HF hospitalisation in the past 12 months (NYHA 2-4), or stable ambulatory with BNP \\> 100 pg/mL or NT-proBNP \\> 300 pg/mL or MR-proANP \\> 120 pmol/L (NYHA 2-4)\n5. Written informed consent\n* Must have minimum age of 18 Years",
    "exclusionCriteria": "1. Hypersensitivity to the active substance, to FCM or any of its excipients\n2. Known serious hypersensitivity to other parenteral iron products\n3. Anaemia not attributed to iron deficiency, e.g. other microcytic anaemia\n4. Evidence of iron overload or disturbances in the utilisation of iron\n5. History of severe asthma with known FEV1 \\<50%\n6. Acute bacterial infection\n7. Presence of a deficiency for vitamin B12 and/or serum folate (if present, this needs to be corrected first)\n8. Use of renal replacement therapy\n9. Treatment with an erythropoietin stimulating agent (ESA), any i.v. iron and/or a blood transfusion in the previous 6 weeks prior to randomisation.\n10. More than 500 meters in the initial 6-minutes walking-test"
}